Intravenous golimumab in rheumatoid arthritis

被引：9

作者：

Cohen, Marc D. ^{[1
]}

Keystone, Edward C. ^{[2
,3
]}

机构：

[1] Mayo Clin, Denver, CO 80218 USA

[2] Univ Toronto, Toronto, ON, Canada

[3] Mt Sinai Hosp, Toronto, ON M5T 3L9, Canada

来源：

EXPERT REVIEW OF CLINICAL IMMUNOLOGY | 2014年 / 10卷 / 07期

关键词：

anti-TNF-; antibodies; golimumab; rheumatoid arthritis treatment; safety of TNF- inhibition; TNF-; inhibition; ALPHA MONOCLONAL-ANTIBODY; NECROSIS-FACTOR-ALPHA; DOUBLE-BLIND; PHASE-III; ANKYLOSING-SPONDYLITIS; METHOTREXATE THERAPY; SAFETY; EFFICACY; PHARMACOKINETICS;

D O I：

10.1586/1744666X.2014.918847

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Intravenous golimumab in a dosage of 2 mg/kg, initially given every 4 weeks but then every 8 weeks, in addition to methotrexate, is effective in the treatment of patients with rheumatoid arthritis. This weight-based infusion is administered over thirty minutes with an acceptable safety profile. Since it is a relatively new formulation, more time will be required to assess its specific role in the rheumatologists' armamentarium and to appreciate more fully its long-term safety.

引用

页码：823 / 830

页数：8

共 50 条

[31] GOLIMUMAB: A NOVEL ANTI-INF-α HUMAN MONOCLONAL ANTIBODY FOR RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS
Campas-Moya, Clara
DRUGS OF TODAY, 2010, 46 (01) : 13 - 22
[32] Long-term golimumab persistence: Five-year treatment retention data pooled from pivotal Phase III clinical trials in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
Weinstein, Cindy L. J.
Meehan, Alan G.
Lin, Jianxin
Briscoe, Steven D.
Govoni, Marinella
CLINICAL RHEUMATOLOGY, 2023, 42 (12) : 3397 - 3405
[33] Golimumab In the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Oldfield, Vicki
Plosker, Greg L.
BIODRUGS, 2009, 23 (02) : 125 - 135
[34] Golimumab for the treatment of axial spondyloarthritis
Palazzi, Carlo
D'angelo, Salvatore
Gilio, Michele
Leccese, Pietro
Padula, Angela
Olivieri, Ignazio
EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (01) : 129 - 133
[35] Golimumab
Mazumdar, Sohini
Greenwald, David
MABS, 2009, 1 (05) : 422 - 431
[36] Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany
Krueger, Klaus
Burmester, Gerd R.
Wassenberg, Siegfried
Bohl-Buehler, Martin
Thomas, Matthias H.
RHEUMATOLOGY INTERNATIONAL, 2019, 39 (01) : 131 - 140
[37] The role of golimumab in inflammatory arthritis. A review of the evidence
Tahir, Zunera
Kavanaugh, Arthur
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2018, 10 (09) : 181 - 194
[38] Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
M. Elaine Husni
Atul Deodhar
Sergio Schwartzman
Soumya D. Chakravarty
Elizabeth C. Hsia
Jocelyn H. Leu
Yiying Zhou
Kim H. Lo
Arthur Kavanaugh
Arthritis Research & Therapy, 24
[39] Golimumab: a new anti-TNF-α agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
Voulgari, Paraskevi V.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2010, 6 (05) : 721 - 733
[40] Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
Rossini, M.
Viapiana, O.
Orsolini, G.
Fracassi, E.
Idolazzi, L.
Gatti, D.
Adami, S.
Govoni, M.
REUMATISMO, 2014, 66 (04) : 285 - 303

← 1 2 3 4 5 →